MIF Facilitates Resistance to Androgen Deprivation Therapy by Regulating AMPD2 Expression in Prostate Cancer Cells

Objective: Androgen deprivation therapy (ADT) was the frontline treatment for patients with prostate Cancer ineligible for radical prostatectomy. However, the development of resistance to ADT significantly limits its clinical efficacy.

Methods: Using a genome-wide CRISPR/Cas9 knockout (GeCKO) library screen combined with single-cell RNA Sequencing (scRNA-seq) analysis, we identified key genes involved in ADT resistance.

Results: Macrophage migration inhibitory factor (MIF) was identified as a critical mediator of ADT resistance. Inhibition of MIF significantly overcomes ADT resistance. Moreover, we found that the Androgen Receptor (AR), but not its splice variant AR-V7, negatively regulates MIF expression. Consequently, inhibition of the AR signaling pathway via ADT results in the upregulation of MIF expression. Elevated expression of MIF promotes prostate Cancer cell proliferation by upregulating AMPD2 expression.

Conclusions: Our findings demonstrate that ADT induces MIF upregulation, which in turn drives prostate Cancer cell proliferation via upregulating AMPD2 expression, eventually contributing to the development of resistance to ADT.

MIF; androgen deprivation therapy; prostate cancer; purine metabolism; resistance.